This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Potassium aspartate is a potassium supplement used to treat hypokalemia or hyperammonemia.
- Generic Name
- Potassium aspartate
- DrugBank Accession Number
- DB15819
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Potassium aspartate (DB15819)
- Weight
- Average: 360.402
Monoisotopic: 359.99734302 - Chemical Formula
- C8H14K2N2O9
- Synonyms
- Aspartate potassium
- L-aspartate potassium
- Monopotassium aspartate hemihydrate
- Potassium aspartate
- Potassium aspartate hemihydrate
- Potassium hydrogen aspartate hemihydrate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Hyperammonaemia •••••••••••• •••••••••• ••••••••• •••••••••••• ••••••••• ••••••••••• Treatment of Hypokalemia •••••••••••• •••••••••• ••••••••• •••••••••••• ••••••••• ••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image C-1000 Plus Zinc & Potassium Potassium aspartate (12 mg) + Calcium ascorbate (1 g) + Potassium citrate (13 mg) + Zinc ascorbate (5 mg) Tablet Oral Nu Life Nutrition Ltd. 1987-12-31 2005-03-15 Canada 
Elozell "forte" - Infusionsflasche Potassium aspartate (2.163 g/250ml) + Magnesium aspartate (2.163 g/250ml) Solution Intravenous Fresenius Kabi Austria Gmb H 1970-12-09 Not applicable Austria 
Elozell "spezial" - Infusionsflasche Potassium aspartate (1.441 g/250ml) + Magnesium aspartate (2.163 g/250ml) + Potassium chloride (1.193 g/250ml) Solution Intravenous Fresenius Kabi Austria Gmb H 1983-01-20 Not applicable Austria FATIGON TABLET Potassium aspartate (100 mg) + Cyanocobalamin (100 mcg) + Magnesium aspartate (100 mg) + Pyridoxine hydrochloride (50 mg) + Thiamine hydrochloride (100 mg) + Vitamin E (30 IU) Tablet Oral THE ZYFAS MEDICAL CO., 2020-09-08 Not applicable Malaysia 
RENAPAR Potassium aspartate (300 mg) + Magnesium aspartate (100 mg) Tablet, film coated Oral Pratapa Nirmala 2017-02-27 2027-02-27 Indonesia 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- OC4598NZEQ
- CAS number
- 7259-25-8
- InChI Key
- YKZPPPNXRZHVGX-PXYKVGKMSA-L
- InChI
- InChI=1S/2C4H7NO4.2K.H2O/c2*5-2(4(8)9)1-3(6)7;;;/h2*2H,1,5H2,(H,6,7)(H,8,9);;;1H2/q;;2*+1;/p-2/t2*2-;;;/m00.../s1
- IUPAC Name
- dipotassium dihydrogen bis((2S)-2-aminobutanedioate) hydrate
- SMILES
- [H+].[H+].O.[K+].[K+].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O
References
- General References
- AIFA Product Information: K FLEBO (potassium aspartate) solution [Link]
- External Links
- ChemSpider
- 34992796
- 8589
- ChEMBL
- CHEMBL3989852
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous Tablet Oral Injection, solution, concentrate Intravenous; Oral 1 mEq/ml Injection, solution, concentrate Intravenous; Oral 3 mEq/ml Injection, solution, concentrate Intravenous; Oral Injection, solution, concentrate Intravenous; Oral; Subcutaneous Injection, solution, concentrate Intravenous; Oral 171.1 mg/ml Injection, solution, concentrate Intravenous; Oral 513.3 mg/ml Tablet, film coated Oral 300 mg Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 644.0 mg/mL ALOGPS logP -0.95 ALOGPS logP -3.5 Chemaxon logS 0.59 ALOGPS pKa (Strongest Acidic) 1.7 Chemaxon pKa (Strongest Basic) 9.61 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 106.28 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 48.21 m3·mol-1 Chemaxon Polarizability 10.57 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 123.3560882 predictedDarkChem Lite v0.1.0 [M+H]+ 123.1701882 predictedDarkChem Lite v0.1.0 [M+Na]+ 122.7319882 predictedDarkChem Lite v0.1.0
Drug created at September 09, 2020 19:17 / Updated at December 01, 2021 03:27